Clinical insights on the diagnosis of NRG1 fusions in patients with non–small cell lung cancer.
Educational support for this activity provided by Merus.
Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.